Dong-A ST announced on March 9 that it has signed a contract with China’s Suzhou Sino on the previous day to exclusively supply “Terizidone,” raw material medicine used in the treatment of multi-drug resistant tuberculosis (TB).
With the latest deal, the company will provide the Chinese company with Terizidone worth at least 25 billion won (US$20.58 million) for five years after the product development is completed in China. Suzhou Sino will have the exclusive rights to develop, commercialize, produce and sell the complete medicine in China, including clinical trials.
Terizidone is a raw material drug that treats patients with multi-drug resistant TB, who have developed resistance to initial TB drugs, particularly Isoniazid and Rifampicin. Last year, 7.1 billion won (US$5.84 million) of Terizidone was exported to five countries besides South Africa.
Established in Suzhou, China, in 2003, Suzhou Sino is an importer and distributor of raw material and complete antibiotic and TB drugs. Dong-A ST signed an exclusive sales contract for “Cycloserine Capsules,” a drug to treat multi-drug resistant TB, with Suzhou Sino in 2014.
Cycloserine Capsules received an approval from China Food and Drug Administration (CFDA) in Dec. 2014. Currently, the product is on sale in four out of 31 provinces in China after winning the bids.
Meanwhile, Dong-A ST signed the exclusive sales contract for “Zydena,” the treatment for erectile-dysfunction, with Shanghai Pharmaceutical Group in 2011, the license-out agreements for “Suganon,” a diabetic drug, with Luye Pharmaceutical Group and for “Monotaxel,” a cancer treatment, with Gloria in 2012, and the export deal for “Entecavir,” a raw material medicine used in the treatment of hepatitis B virus (HBV) infection, with another Chinese pharmaceutical company in 2013, seeking to expand its business into China.